Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.24M | 20.18M | 17.73M | 17.27M | 16.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.24M | 20.18M | 17.73M | 17.27M | 16.61M |
| Cost of Revenue | 4.66M | 4.62M | 3.54M | 3.50M | 3.52M |
| Gross Profit | 15.58M | 15.57M | 14.19M | 13.77M | 13.09M |
| SG&A Expenses | 16.58M | 17.08M | 19.54M | 20.50M | 20.54M |
| Depreciation & Amortization | 351.00K | 499.00K | 728.00K | 949.00K | 842.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.69M | 18.74M | 20.64M | 21.64M | 21.11M |
| Operating Income | -3.46M | 1.44M | -2.91M | -4.37M | -4.51M |
| Income Before Tax | -6.03M | 393.00K | -5.43M | -6.23M | -3.10M |
| Income Tax Expenses | 1.00K | 2.00K | 3.00K | -1.00K | 0.00 |
| Earnings from Continuing Operations | -6.03 | 0.39 | -5.43 | -6.23 | -3.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.03M | 391.00K | -5.43M | -6.23M | -3.10M |
| EBIT | -3.46M | 1.44M | -2.91M | -4.37M | -4.51M |
| EBITDA | -3.09M | 1.96M | -2.16M | -3.40M | -3.64M |
| EPS Basic | -0.05 | 0.00 | -0.05 | -0.06 | -0.03 |
| Normalized Basic EPS | -0.04 | -0.01 | -0.04 | -0.04 | -0.01 |
| EPS Diluted | -0.08 | -0.03 | -0.06 | -0.07 | -0.05 |
| Normalized Diluted EPS | -0.05 | -0.03 | -0.05 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 514.45M | 499.37M | 459.21M | 436.09M | 387.18M |
| Average Diluted Shares Outstanding | 25.71B | 31.73B | 6.50B | 6.47B | 7.97B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |